| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1034983299 |
| P356 | DOI | 10.1007/S40264-016-0427-8 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s40264-016-0427-8 |
| P698 | PubMed publication ID | 27142208 |
| P2093 | author name string | James H Lewis | |
| Joshua M Steinberg | |||
| Philip Sarges | |||
| P2860 | cites work | Can AST/ALT ratio indicate recovery after acute paracetamol poisoning? | Q86660392 |
| [RUCAM scale-based diagnosis, clinical features and prognosis of 140 cases of drug-induced liver injury] | Q86668244 | ||
| Methylprednisolone-induced hepatotoxicity: experiences from global adverse drug reaction surveillance | Q87024749 | ||
| New biomarkers for drug-induced liver injury: are they really better? What do they diagnose? | Q87049199 | ||
| High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury | Q87167186 | ||
| The PCSK9 decade | Q24615397 | ||
| Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure | Q24635175 | ||
| Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States | Q26767296 | ||
| Current Knowledge on Hepatitis E | Q26782030 | ||
| LDL cholesterol, statins and PCSK 9 inhibitors | Q26782522 | ||
| Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis | Q26785746 | ||
| Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods | Q26824747 | ||
| Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases | Q26864098 | ||
| Liver safety assessment in special populations (hepatitis B, C, and oncology trials) | Q27008502 | ||
| Enoxaparin-Induced Liver Injury: Case Report and Review of the Literature and FDA Adverse Event Reporting System (FAERS) | Q28074812 | ||
| Rivaroxaban postmarketing risk of liver injury | Q28237054 | ||
| Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury | Q28237500 | ||
| Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system | Q28257188 | ||
| Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry | Q28276237 | ||
| HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity | Q28534593 | ||
| The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01 | Q28548544 | ||
| Liver transplant associated with paracetamol overdose: results from the seven-country SALT study | Q28607494 | ||
| HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin | Q29417159 | ||
| Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review | Q30277969 | ||
| The mystery of the Hawaii liver disease cluster in summer 2013: A pragmatic and clinical approach to solve the problem | Q40253110 | ||
| Risk Factors, Clinical Presentation, and Outcomes in Overdose With Acetaminophen Alone or With Combination Products: Results From the Acute Liver Failure Study Group | Q40746487 | ||
| "Drug-Induced Liver Injury Clinical Consortia: a global research response for a worldwide health challenge". | Q40945776 | ||
| Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis: Patient characteristics, causes, and outcome in 36 cases | Q40965073 | ||
| Severe liver injury associated with simeprevir plus pegylated interferon/ribavirin therapy in a patient with treatment-naïve genotype 1b hepatitis C virus: a case report | Q41104105 | ||
| New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease | Q41256627 | ||
| Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial | Q41289477 | ||
| Association study of UGT1A9 promoter polymorphisms with DILI based on systematically regional variation screen in Chinese population | Q41636182 | ||
| Blood alanine aminotransferase levels >1,000 IU/l - causes and outcomes. | Q41703063 | ||
| Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis | Q42180870 | ||
| Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts | Q42263059 | ||
| Flow cytometry analysis with a new FITC-conjugated monoclonal antibody-3E12 for HLA-B*57:01 rapid screening in prevention of abacavir hypersensitivity in HIV-1-infected patients | Q42278364 | ||
| Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. | Q43050091 | ||
| Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events | Q43259278 | ||
| The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study. | Q44075475 | ||
| Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. | Q45909196 | ||
| The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice | Q46156278 | ||
| PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial | Q46215056 | ||
| The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity | Q46835446 | ||
| Model for end-stage liver disease score as a predictor of short-term outcome in patients with drug-induced liver injury | Q47441166 | ||
| Outbreak of severe hepatitis linked to weight-loss supplement OxyELITE Pro. | Q47444587 | ||
| Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases. | Q49022529 | ||
| Drug-induced liver injury in a chronic hepatitis C patient treated by peginterferon, ribavirin and simeprevir. | Q50279223 | ||
| Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis. | Q51012583 | ||
| Natural history and outcomes in drug-induced autoimmune hepatitis. | Q51027472 | ||
| Paracetamol overdose in Hong Kong: is the 150-treatment line good enough to cover patients with paracetamol-induced liver injury? | Q51285621 | ||
| ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury | Q60962648 | ||
| Use of apixaban after development of suspected rivaroxaban-induced hepatic steatosis; a case report | Q85556160 | ||
| Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial | Q85678153 | ||
| High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury | Q85758004 | ||
| Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir | Q85762617 | ||
| Severe hepatotoxicity associated with asunaprevir and daclatasvir in chronic hepatitis C | Q85846172 | ||
| Drug-induced acute liver failure | Q86481862 | ||
| Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. | Q30301355 | ||
| Hepatotoxicity associated with agomelatine and other antidepressants: Disproportionality analysis using pooled pharmacovigilance data from the Uppsala Monitoring Centre | Q30887490 | ||
| Eculizumab hepatotoxicity in pediatric aHUS. | Q33418797 | ||
| The natural history of histologically proved drug induced liver disease | Q33594865 | ||
| Hy's law. | Q34295400 | ||
| Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges | Q34417044 | ||
| Hepatotoxicity of herbal and dietary supplements: an update | Q34462677 | ||
| Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk | Q34499496 | ||
| Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset | Q34848118 | ||
| Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study | Q34921780 | ||
| Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network | Q34943114 | ||
| Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). | Q35009149 | ||
| Clinical and histologic features of azithromycin-induced liver injury | Q35064690 | ||
| Drug-induced liver injury: the dawn of biomarkers? | Q35210890 | ||
| An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury. | Q35644034 | ||
| Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system | Q35655664 | ||
| Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study | Q35656015 | ||
| Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study | Q35684831 | ||
| MicroRNAs as Signaling Mediators and Biomarkers of Drug- and Chemical-Induced Liver Injury. | Q35750622 | ||
| Identification and Characterization of Cefazolin-Induced Liver Injury. | Q35756589 | ||
| Albumin Dialysis for Liver Failure: A Systematic Review | Q35756887 | ||
| Causes, Features, and Outcomes of Drug-Induced Liver Injury in 69 Children from China | Q35771883 | ||
| Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases | Q35783976 | ||
| A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury | Q35786010 | ||
| Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk | Q35819331 | ||
| Viral hepatitis prevalence in patients with active and latent tuberculosis | Q35925537 | ||
| The Role of Adverse Event Reporting in the FDA Response to a Multistate Outbreak of Liver Disease Associated with a Dietary Supplement | Q35930709 | ||
| Extracorporeal liver assist device to exchange albumin and remove endotoxin in acute liver failure: Results of a pivotal pre-clinical study | Q35970399 | ||
| Potential of extracellular microRNAs as biomarkers of acetaminophen toxicity in children | Q36022680 | ||
| Herbal medicine-related hepatotoxicity | Q36033537 | ||
| Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study | Q36104706 | ||
| Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database | Q36171663 | ||
| Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. | Q36187981 | ||
| Drug-induced liver injury: Interactions between drug properties and host factors | Q38442310 | ||
| Liver dialysis in acute-on-chronic liver failure: current and future perspectives. | Q38442903 | ||
| Characteristics of liver injury in drug-induced systemic hypersensitivity reactions | Q38450840 | ||
| The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond | Q38538885 | ||
| Hepatotoxicity of New Oral Anticoagulants (NOACs). | Q38542198 | ||
| Systematic review on herb-induced liver injury in Korea | Q38545581 | ||
| Drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome: clinical features of 27 patients | Q38566296 | ||
| Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports | Q38620305 | ||
| Methylprednisolone-induced liver injury: Case report and literature review | Q38671657 | ||
| Use of Pediatric Health Information System database to study the trends in the incidence, management, etiology, and outcomes due to pediatric acute liver failure in the United States from 2008 to 2013. | Q38962023 | ||
| Estimating heritability of drug-induced liver injury from common variants and implications for future study designs | Q39157109 | ||
| Liver injury in patients with DRESS: A clinical study of 72 cases. | Q40163982 | ||
| Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity | Q36299913 | ||
| Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model | Q36304927 | ||
| CSF1 Restores Innate Immunity After Liver Injury in Mice and Serum Levels Indicate Outcomes of Patients With Acute Liver Failure | Q36353138 | ||
| Continuous molecular adsorbent recirculating system treatment in 69 patients listed for liver transplantation | Q36357186 | ||
| Variability in Acetaminophen Labeling Practices: a Missed Opportunity to Enhance Patient Safety | Q36362741 | ||
| Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. | Q36431416 | ||
| Hepatotoxicity Associated with the Use of Anti-TNF-α Agents | Q36576535 | ||
| Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses | Q36594917 | ||
| Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury | Q36668300 | ||
| Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct | Q36799781 | ||
| Hepatotoxicity associated with the dietary supplement OxyELITE Pro™ - Hawaii, 2013. | Q36804015 | ||
| Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury | Q36845686 | ||
| Drug-Induced Liver Injury during Antidepressant Treatment: Results of AMSP, a Drug Surveillance Program | Q36852416 | ||
| N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review. | Q36924709 | ||
| The role of hepatitis E virus testing in drug-induced liver injury. | Q36938489 | ||
| Clinical and histopathologic features of fluoroquinolone-induced liver injury. | Q37031426 | ||
| Catechins in dietary supplements and hepatotoxicity | Q37161272 | ||
| Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital | Q37346819 | ||
| Drug-induced acute liver failure: results of a U.S. multicenter, prospective study | Q37711165 | ||
| Clinical perspective: statins and the liver--harmful or helpful? | Q38009719 | ||
| Stratification of paracetamol overdose patients using new toxicity biomarkers: current candidates and future challenges | Q38180741 | ||
| miRNAs and their application in drug-induced liver injury | Q38187448 | ||
| Drug-induced liver injury: what was new in 2013? | Q38205591 | ||
| Future of pharmacogenetics-based therapy for tuberculosis | Q38209573 | ||
| Mechanistic biomarkers in acetaminophen-induced hepatotoxicity and acute liver failure: from preclinical models to patients | Q38212434 | ||
| Review article: Herbal hepatotoxicity--an update on traditional Chinese medicine preparations | Q38213152 | ||
| Genetic basis of drug-induced liver injury: present and future | Q38216267 | ||
| Hepatotoxicity induced by herbal and dietary supplements | Q38216271 | ||
| Severe ductopenia and cholestasis from levofloxacin drug-induced liver injury: a case report and review | Q38216277 | ||
| Experience with OxyELITE pro and acute liver injury in active duty service members | Q38219315 | ||
| Human leukocyte antigen genetic risk factors of drug-induced liver toxicology | Q38285818 | ||
| Ipilimumab-induced toxicities and the gastroenterologist. | Q38340321 | ||
| Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice | Q38391340 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 801-821 | |
| P577 | publication date | 2016-05-03 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature | |
| P478 | volume | 39 |
| Q40981164 | A case of reversible drug-induced liver failure |
| Q47196385 | A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies. |
| Q39112273 | A rapid assessment for predicting drug-induced hepatotoxicity using zebrafish |
| Q64068409 | Clonazepam-induced liver dysfunction, severe hyperlipidaemia, and hyperglycaemic crisis: A case report |
| Q45943038 | Development of Decision Forest Models for Prediction of Drug-Induced Liver Injury in Humans Using A Large Set of FDA-approved Drugs. |
| Q39125114 | Diagnosis and Treatment of Hyponatremia: Compilation of the Guidelines |
| Q92354275 | Diagnostic Biomarkers in Liver Injury by Drugs, Herbs, and Alcohol: Tricky Dilemma after EMA Correctly and Officially Retracted Letter of Support |
| Q40313991 | Diphenhydramine as a Cause of Drug-Induced Liver Injury. |
| Q39234138 | Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment? |
| Q39037269 | Drug metabolism and liver disease: a drug-gene-environment interaction |
| Q52675513 | Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch? |
| Q28468389 | Drug-induced liver injury: Towards early prediction and risk stratification |
| Q64996856 | Evaluation of naproxen-induced oxidative stress, hepatotoxicity and in-vivo genotoxicity in male Wistar rats. |
| Q44838603 | Hepatitis: Sedation and Anesthesia Implications |
| Q47166492 | Hepatotoxicity of Herbal Supplements Mediated by Modulation of Cytochrome P450. |
| Q55286744 | Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials. |
| Q92510476 | Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019 |
| Q38784195 | Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM. |
| Q92649547 | Roussel Uclaf Causality Assessment Method for Drug-Induced Liver Injury: Present and Future |
| Q47342608 | Suspected Liver Injury and the Dilemma of Causality |
| Q41747844 | Traditional Chinese Medicine (TCM) and Herbal Hepatotoxicity: RUCAM and the Role of Novel Diagnostic Biomarkers Such as MicroRNAs |
| Q55470655 | Traditional Chinese Medicine and Herb-induced Liver Injury: Comparison with Drug-induced Liver Injury. |
Search more.